# Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer

> **NCT06636591** · NA · RECRUITING · sponsor: **Fudan University** · enrollment: 14 (estimated)

## Conditions studied

- Breast Cancer Female
- HER2-negative Breast Cancer

## Interventions

- **COMBINATION_PRODUCT:** Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin
- **COMBINATION_PRODUCT:** Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Goserelin

## Key facts

- **NCT ID:** NCT06636591
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-18
- **Primary completion:** 2025-02-07
- **Final completion:** 2026-10-07
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2024-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06636591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06636591, "Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06636591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*